Scientific Program

Conference Series LLC Ltd invites all the participants across the globe to attend 26th Annual Conference on Clinical & Medical Case Reports in Cardiology Golden Tulip Berlin – Hotel Hamburg.

Day 2 :

Keynote Forum

Alicja Jozkowicz

Jagiellonian University, Poland

Keynote: Nrf2 and Keap1: A quintessential duet in endothelial cells

Time : 09:00-09:30

Cardiology Case Reports 2018 International Conference Keynote Speaker Alicja Jozkowicz photo
Biography:

Abstract:

Nrf2 is a transcription factor known to modulate blood vessel formation. Various experimental settings, however, attribute to Nrf2 either stimulatory or repressive effects on angiogenesis. Our findings unveil the mechanism of Nrf2-dependent vessel formation, which reaches beyond transactivation of gene expression and reconciles previous discrepancies. We evidence that GDF-15- and SDF-1-induced angiogenesis strongly depends on the presence of Nrf2 protein, but does not rely on its transcriptional activity. Instead, Nrf2 serves as a protein restraining Keap1, its known transcriptional repressor. Angiogenic response is abrogated in Nrf2-deficient endothelial cells but not in cells expressing dominant negative form or Keap1-binding fragment of Nrf2. Deficiency of Nrf2 protein available for Keap1 leads to the overabundance of RhoGAP1, the protein regulating Cdc42 activity. This impairs podosome assembly and disrupts actin rearrangements, thereby preventing angiogenesis. Effects of Nrf2 deficiency can be rescued by concomitant knock down of RhoGAP1 or Keap1. Importantly, in the established murine model of Nrf2 deficiency, the N-terminal fragment of Nrf2 containing Keap1 binding domain is preserved. Thus, this model can be used to characterize Nrf2 as a transcription factor, but not as a Keap1-sequestering protein. Up to date the significance of Nrf2 in cell function has been ascribed solely to regulation of transcription. We demonstrate that Nrf2 serves a protein tethering Keap1 to allow podosome assembly and angiogenesis.
 

Keynote Forum

Sekib Sokolovic

Sarajevo University, Bosnia and Herzegovina

Keynote: Cigarette smokers and arterial stiffness

Time : 09:30-10:00

Cardiology Case Reports 2018 International Conference Keynote Speaker Sekib Sokolovic photo
Biography:

Sekib Sokolovic is a Professor of Internal Medicine at Medical Faculty of Sarajevo University and Cardiologist at Sarajevo University Clinical Center. He is a European Hypertension Specialist and Director of National Training in Cardiology and Director of the Excellence Center in Arterial Hypertension. His expertise is arterial stiffness, vitamin D, arterial hypertension, microcirculation and pulmonary arterial hypertension. He is an invited speaker worldwide and key speaker as well.
 

Abstract:

Introduction: The correlation between the arterial stiffness and tobacco users has been verified in a clinical study. Increased arterial stiffness contributes to increased vascular calcifications and atherosclerotic disease and all cardiovascular mortality. Cigarette smokers contribute to 6 million deaths per year globally. Measurement of the arterial stiffness has been recommended in the ESC/ESH guidelines for the arterial hypertension. Material & Method: In order to evaluate the arterial stiffness, the measurement of aortic pulse wave velocity, (APWV), augmentation index (AI), stroke volume, (SV), the reflection gradient (RC) was performed using Agedio Arteriograph. The estimation of cardiovascular risk factors was performed in all examined patients and two groups were formed. One group included smokers and the other one non-smoker healthy subjects. The open outpatient controlled prospective study has been designed. The cardiovascular others risk factors were evaluated in all. Results: Preliminary results obtained have shown the significant increase in APWV, augmentation index and reflection index in smokers group compared to normal arterial stiffness values in non-smokers. Conclusion: These preliminary results have shown that arterial stiffness has been significantly increased in a smoker group whereas the average vascular age has been increased. This finding is additional evidence for the cigarette smoking as risk factor for early vascular pathophysiological changes. The measurements of these parameters are necessary for the cardiovascular risk disease prevention. 

Cardiology Case Reports 2018 International Conference Keynote Speaker Marco Piciche photo
Biography:

Marco Picichè (MD, Ph.D.) graduated with a degree in medicine from the University of Florence in 1995 and completed his cardiac surgery residency at the Tor Vergata University of Rome in 2000, both summa cum laude. He held regular teaching appointments at the university of Montpellier school of medicine, obtained certification by the French Board in cardiac surgery (Paris, 2007), earned his research master in surgical science (Paris, 2007), and received a university diploma in vascular surgery (Paris, 2007). In May 2009 he had the honor of opening the 44th Congress of the European Society for Surgical Research with a lecture on ‘‘The history of surgical research.’’ In September 2011 he received a doctor of philosophy (Ph.D.) in therapeutic innovations from Paris-Sud University. He is the Editor in Chief of the book : « Dawn and evolution of cardiac procedures : research avenues in cardiac surgery and interventional cardiology » (Springer-Verlag publishing house, September 2012). He patented a new surgical instrument. Currently he is a cardiac surgeon in Italy.
 

Abstract:

No one knows the true incidence of refractory angina, but it is generally agreed that there are thousands new cases annually. The incidence will presumably increase with the increase of average age. Patients suffering from refractory angina are known as no-option, because they are not amenable to coronary artery bypass grafting or percutaneous coronary interventions. The main reason to be unamenable to conventional revascularization techniques is a diffuse coronary disease, and secondarily comorbidities. Several alternative methods have been advocated, such as stem cell therapy, external counter-pulsation, laser transmyocardial revascularization sympathectomy, partial occlusion of the coronary sinus, shock wave myocardial revascularization. The internal mammary artery (IMAs) has the potential for developing collateral branches under some circumstances. This was the basis for an old operation performed in the 1940s, i.e. the tunnellization of the IMAs in to the left ventricle free wall. 

Keynote Forum

Lale Hakami

University of Munich, Germany

Keynote: Single center results after cardiac transplantation in infants and small children

Time : 10:30-11:05

Cardiology Case Reports 2018 International Conference Keynote Speaker Lale Hakami photo
Biography:

Lale Hakami has her expertise in pediatric cardiac surgery in infants and newborn. She is a German-board-certified cardiac surgeon with a subspecialization in pediatric cardiac surgery. From 2006-2008, she was the junior consultant of the Congenital Heart Surgery at the University Hospital Erlangen/Germany. From 2008-2009, she was Research Fellowship at the Children's Hospital Boston/USA. From 2009 to 2011 she was director of pediatric cardiac surgery in Mainz/Germany.  From 2011-2014 she was senior consultant in children heart center in Linz/Austria. From 2014 she is senior consultant at the University Hospital Munich/Germany and University Lecture of Pediatric Cardiac Surgery at Ludwig-Maximilians-University Munich/Germany (LMU). Her particular experience is in single ventricle physiology and heart transplantation in infants and newborn.
 

Abstract:

Objectives: Heart transplantation is the last surgical option for infants and young children with congenital heart failure after failed conventional repair or palliative procedures. We aim to present our results in a retrospective and descriptive analysis. Methods: 18 heart transplantations on children (nine female, nine male) were performed from 1988 to 2015. The range of age was between 0 days and 3 years. Indications for a transplantation were hypoplastic left heart syndrome (n=14), non-compactionsyndrome (n=2), Bland-White-Garland-syndrome (n=1) and transposition of the great arteries (n=1). 14 children (78%) had had a previous cardiac surgery. Four patients (22%) required mechanical circulatory support for bridging: ECMO (n=2; 11%), or LVAD and ECMO (n=2; 11%). 15 (83%) underwent a biatrial method, three (17%) a bicaval one. Results: The median waiting time after listing was 68 days (min: 0 days, max: 386 days, standard deviation (SD): 102.8 days). The overall survival was 61%, 13 children (72%) survived the first year. Two patients (11%) had a retransplantation. The median time patients spent at intensive care unit was 17 days (min: 1 day; max: 121 days). They were respirated for seven days (min: 1 day; max: 91 days). Perioperative factors we analyzed were: the median myocardial ischemia time was 236 minutes; the median aortic clamp time was 95 minutes and the median time of circulatory arrest was 60 minutes. Three children (17%) got a pericardial effusion. Two patients (11%) suffered each: bleeding, cardiac arrhythmias, diaphragmatic paresis and cerebral complications. Five (28%) got a lymphoproliferative disease. Seven children (39%) got a coronary graft vasculopathy. Two (11%) needed interventional therapy. Three (17%) got a cardiac pace maker. According to our data, six children had a rejection which called for treatment. Conclusion: Heart transplantation is still the best therapeutic option after end-stage heart failure in children. Cumulative results suggest one additional year of life in more than 70% and a survival of more than 20 years are possible. These results were comparable to those of the ISHLT registry in pediatrics.